FindTrial
Sign In

A Comparative Study of Bleomycin injection versus Tuberculin Purified Protein Derivative injection in cutaneous warts.

A Comparative study of intralesional Bleomycin injection versus Tuberculin Purified Protein Derivative in the treatment of cutaneous warts: A prospective study from a tertiary care centre. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085453
Enrollment
60
Registered
2025-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Injection Bleomycin: 1 vial of injection bleomycin containing 15 IU is diluted with 5 ml of normal saline to prepare the stock solution.(15 IU/5 ml). follow up baseline, every 3rd week

Sponsors

Eras Lucknow Medical College and Hospital Lucknow
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who have not taken any treatment for warts in the past 4 weeks.

Exclusion criteria

Exclusion criteria: 1 Patients with local skin infection, hypersensitivity to Bleomycin, allergic skin diseases. 2 Pregnant and lactating women 3 Immunosuppressed patients or patients on immunosuppressive therapy 4 Patients with history of any other systemic illness. 5 Patients refusing consent.

Design outcomes

Primary

MeasureTime frame
To compare the response of Intralesional bleomycin better than tuberculin purified protein derivative in cases of cutaneous wartsTimepoint: baseline, then every 3 weeks till resolution of lesions—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactMoin Ahmad Siddiqui

Eras Lucknow Medical College and Hospital

moinahmad12@gmail.com8218382301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026